Analysts Truist upgraded Biogen (BIIB) to Buy and raised target price to $235 on positive drug trial data expectations
Truist Securities has upgraded Biogen to 'buy' and raised its price target, anticipating positive data from upcoming trials for its Alzheimer's treatment, which could significantly boost the company's stock.